

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - What NHS-Galleri taught us—and what it didn’t
- Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital














